Top Page
Shanghai Henlius Biotech, Inc. Class H
(2696)
Shanghai Henlius Biotech, Inc. Class H (2696) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Henlius Biotech, Inc. Class H Business Overview & Revenue Model
Shanghai Henlius Biotech, Inc. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.80B | 5.72B | 5.39B | 3.21B | 1.68B | 587.59M |
| Gross Profit | 4.39B | 4.18B | 3.92B | 2.37B | 1.16B | 405.47M |
| EBITDA | 1.14B | 1.15B | 911.33M | -310.61M | -671.74M | -814.06M |
| Net Income | 824.30M | 820.47M | 546.02M | -695.26M | -984.05M | -993.54M |
Balance Sheet | ||||||
| Total Assets | 11.55B | 10.60B | 9.90B | 8.92B | 7.17B | 6.44B |
| Cash, Cash Equivalents and Short-Term Investments | 972.50M | 772.96M | 1.01B | 680.48M | 742.32M | 1.11B |
| Total Debt | 3.67B | 3.65B | 4.09B | 3.68B | 2.62B | 1.83B |
| Total Liabilities | 8.14B | 7.58B | 7.71B | 7.29B | 4.88B | 3.24B |
| Stockholders Equity | 3.41B | 3.01B | 2.19B | 1.64B | 2.30B | 3.20B |
Cash Flow | ||||||
| Free Cash Flow | 930.30M | 404.68M | 36.48M | -383.67M | -1.04B | -2.12B |
| Operating Cash Flow | 990.62M | 1.24B | 1.05B | 981.62M | 90.39M | -609.58M |
| Investing Cash Flow | -123.16M | -909.97M | -1.00B | -1.36B | -1.68B | -1.51B |
| Financing Cash Flow | 0.00 | -643.37M | 144.43M | 858.02M | 648.30M | 995.79M |
Shanghai Henlius Biotech, Inc. Class H Technical Analysis
Shanghai Henlius Biotech, Inc. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$32.96B | 36.97 | 27.37% | ― | 2.57% | 18.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$20.98B | -14.30 | -161.12% | ― | -56.94% | -190.36% | |
42 Neutral | HK$15.05B | -9.08 | -30.41% | ― | 23.87% | 30.08% | |
40 Underperform | HK$19.88B | -93.34 | -3.36% | ― | 58.24% | 38.85% | |
38 Underperform | HK$36.45B | -21.91 | -15.06% | ― | 38.56% | 48.26% |
Shanghai Henlius Biotech, Inc. Class H Corporate Events
Shanghai Henlius Biotech, Inc. announced that its product, FUTUONING (Fovinaciclib Citrate Capsules), has been included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance for 2025. This inclusion, effective from January 2026, is expected to enhance the drug’s accessibility for patients with hormone receptor-positive and HER2-negative breast cancer, thereby benefiting the company’s marketing and sales efforts.
Shanghai Henlius Biotech, Inc. has entered into collaboration agreements with Avanc Pharma to commercialize Fovinaciclib Citrate Capsules, a CDK4/6 inhibitor for HR+ and HER2-breast cancer, in China. This collaboration aligns with Henlius’s strategic focus on breast cancer treatments and is expected to enhance its product offerings and revenue potential. The agreements involve connected transactions under Hong Kong’s Listing Rules, with specific financial and operational implications for Henlius, but they are exempt from independent shareholders’ approval due to the transaction size.
Shanghai Henlius Biotech, Inc. has renewed its distribution collaboration with Sinopharm, extending the agreement until December 2028. This renewal, subject to Hong Kong Listing Rules, positions Sinopharm as a key distributor of Henlius’s products, impacting the company’s market reach and operational strategy. The agreement’s renewal underscores the strategic importance of Sinopharm in Henlius’s distribution network and involves compliance with connected transaction regulations, necessitating shareholder approval and independent financial advice.
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting scheduled for December 31, 2025, to consider the approval of the Sinopharm Distribution Framework Agreement (2025 Renewal). This agreement, if approved, will facilitate continued collaboration with Sinopharm Group Co. Ltd., potentially enhancing the company’s distribution capabilities and market reach in the pharmaceutical sector.
Shanghai Henlius Biotech, Inc. announced that its New Drug Application for HLX14, a biosimilar of denosumab, has been accepted by the National Medical Products Administration in China. This development marks a significant step for the company as HLX14 has already been approved in the US, EU, and UK, and its acceptance in China could enhance the company’s market presence in the osteoporosis treatment sector, given the global sales of denosumab reaching approximately $7.463 billion in 2024.
Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX37, a recombinant humanised bispecific antibody targeting PD-L1 and VEGF, has been approved by the National Medical Products Administration for phase 1 clinical trials. HLX37 aims to treat advanced or metastatic solid tumors by simultaneously blocking PD-1/PD-L1 binding and inhibiting angiogenesis, showing promising pre-clinical results in tumor growth inhibition and safety. This development positions the company to potentially enhance its market presence in the bispecific antibody sector, although the successful commercialization of HLX37 is not guaranteed.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in an international multicenter phase 1 clinical study of its Ipilimumab biosimilar, HLX13, for treating unresectable hepatocellular carcinoma (HCC) in mainland China. This study aims to evaluate the pharmacokinetics, safety, efficacy, and immunogenicity of HLX13 compared to the reference product YERVOY, with the potential to impact the company’s market positioning in the oncology sector significantly.
Shanghai Henlius Biotech, Inc. announced that its HANSIZHUANG (serplulimab injection), in combination with chemotherapy, has received Breakthrough Therapy Designation from China’s National Medical Products Administration for the treatment of gastric cancer. This designation highlights the potential impact of HANSIZHUANG on cancer treatment and strengthens the company’s position in the oncology market, potentially benefiting stakeholders through enhanced treatment options and market expansion.
Shanghai Henlius Biotech, Inc. has announced that its biosimilar product, HLX11 (pertuzumab-dpzb), branded as POHERDY® in the United States, has received FDA approval for use in treating HER2-positive early and metastatic breast cancer. This approval marks a significant milestone for the company, enhancing its international presence and influence, particularly in the U.S. market, and is expected to boost its collaboration with Organon LLC for commercial sales.
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius USA Inc., has received Orphan-drug Designation from the U.S. FDA for HLX43, an anti-PD-L1 antibody-drug conjugate, for the treatment of thymic epithelial tumors. This designation provides the company with benefits such as tax credits, fee exemptions, and market exclusivity, which could enhance its competitive positioning in the oncology market, particularly in the U.S., where no similar PD-L1 targeting ADCs have been approved.
Shanghai Henlius Biotech, Inc. announced that its phase 3 clinical study of HANSIZHUANG (serplulimab injection) in combination with chemotherapy for the treatment of early-stage gastric cancer met its primary endpoint of event-free survival. This significant finding supports an early new drug application submission, indicating a promising advancement in cancer treatment. The study demonstrated a notable improvement in the pathological complete response rate and a reduction in recurrence risk, with a favorable safety profile, enhancing the company’s position in the oncology market.
Shanghai Henlius Biotech, Inc. announced the approval of its phase 1b/2 clinical trial application for HLX43, an anti-PD-L1 antibody-drug conjugate, in combination with HLX07 for treating advanced/metastatic solid tumors. This approval by the National Medical Products Administration marks a significant step in the company’s clinical development efforts, potentially enhancing its market position in oncology therapeutics. The trial’s previous data demonstrated promising results, showing high response rates and good safety profiles, especially in patients with advanced non-small cell lung cancer, indicating a positive outlook for stakeholders.
Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX13, a biosimilar of Ipilimumab, was approved by the FDA for a phase 1 clinical trial as a first-line treatment for unresectable hepatocellular carcinoma. This approval marks a significant step for the company in expanding its clinical trials internationally, potentially enhancing its market position in the oncology sector and providing new treatment options for various cancers.
Shanghai Henlius Biotech, Inc. has initiated an international multi-center phase 1 clinical trial for HLX17, a biosimilar of pembrolizumab, in patients with multiple resected solid tumors in mainland China. This trial aims to evaluate the pharmacokinetic profile, efficacy, safety, and immunogenicity of HLX17 compared to KEYTRUDA, with plans to expand the trial to the United States, Europe, and Australia. The announcement marks a significant step in the company’s efforts to position itself in the global oncology market, leveraging the high global sales of pembrolizumab, which reached approximately USD 32.056 billion in 2024.
Shanghai Henlius Biotech, Inc. announced that the European Commission has approved the marketing authorization applications for two of its products, BILDYOS® and BILPREVDA®, for the treatment of osteoporosis and other bone-related conditions in the EU and EEA countries. This approval is based on extensive comparative studies demonstrating the similarity of HLX14 to the reference product, Prolia®, and marks a significant step in the company’s global expansion strategy, potentially impacting its market positioning and stakeholder interests.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in Australia in its international multicentre phase 2 clinical study of HLX43, an anti-PD-L1 antibody-drug conjugate, for advanced non-small cell lung cancer (NSCLC). The study, also ongoing in mainland China and the United States, aims to evaluate the efficacy and safety of HLX43. Previous phase 1 results demonstrated promising response rates and safety profiles, particularly in patients with advanced tumors who have not responded to other treatments, indicating potential significant impact on the company’s market positioning in oncology therapeutics.
Shanghai Henlius Biotech, Inc. announced that the U.S. FDA has approved the investigational new drug application for HLX17, a biosimilar of pembrolizumab, for phase 1 clinical trials. This approval marks a significant step for the company as it aims to conduct international multi-center trials, potentially enhancing its position in the oncology market, where pembrolizumab sales reached approximately USD 32.056 billion in 2024.